Maintenance of genomic stability is essential for prevention of undue cell death or neoplasia ([@bib10]). Critical DNA lesions, such as double-strand breaks (DSBs), activate the DNA damage response (DDR)---a widespread signaling network that involves DNA repair, activation of cell cycle checkpoints, and extensive modulation of gene expression and many metabolic pathways ([@bib13]; [@bib22]). DSBs are induced by ionizing radiation, radiomimetic chemicals, and endogenous oxygen radicals. They accompany replication fork stalling and are formed and resealed in meiotic recombination and the rearrangement of the antigen receptor genes during the development of the immune system. Major repair pathways for DSBs are error-prone nonhomologous end joining (NHEJ) or high-fidelity homologous recombination repair (HRR; [@bib23]; [@bib26]). The broad, powerful signaling network evoked by DSBs begins with rapid accumulation at DSB sites of a large group of proteins dubbed "sensors" or "moderators" and continues with the activation of several protein kinases ("transducers") with partially redundant functions that relay the signal to numerous downstream effectors, which are typically key players in the various DDR branches ([@bib27]; [@bib13]; [@bib28]).

The primary transducer of the DSB alarm is the serine-threonine kinase ataxia telangiectasia (A-T) mutated (ATM; [@bib3]; [@bib9]), which is activated in response to DSB induction ([@bib2]) and goes on to phosphorylate a plethora of substrates ([@bib29]; [@bib7]). ATM belongs to a conserved family of phosphoinositide 3-kinase--like protein kinases (PIKKs) that includes, among others, two other major DDR transducers: the catalytic subunit of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and ATR (ataxia telangiectasia and Rad3 related). These three kinases maintain close functional relationships ([@bib27]). Recent evidence suggests that ATM's broad capacity as a protein kinase enables it to regulate other processes, such as oxidative stress levels ([@bib20]), and play a role in cytoplasmic, non-DDR arenas, among them mitochondrial homeostasis ([@bib38]; [@bib34]; [@bib35]).

Human germline mutations that abrogate cellular responses to DNA damage cause severe genomic instability syndromes ([@bib24]). The *ATM* gene is mutated in the genomic instability syndrome, A-T ([@bib33]). A-T is characterized by progressive neurodegeneration, immunodeficiency, cancer predisposition, genomic instability, and sensitivity to DSB-inducing agents ([@bib30]). The disease is caused by null *ATM* mutations, and the patients usually exhibit complete loss of the ATM protein ([@bib17]).

Studies of ATM-dependent processes typically rely on human wild-type versus A-T cells, ATM knockdown using RNAi, reconstitution of ATM-deficient cells by ectopic expression of wild-type or kinase-dead ATM protein, or treating cultured cells with ATM inhibitors. Laboratories using these experimental systems have long felt that the physiological consequences of ATM loss as opposed to harboring inactive ATM may not be similar ([@bib12]). The papers by Daniel et al. and Yamamoto et al. (both in this issue) provide solid evidence of this notion and mark a turning point in our view of ATM's mode of function. Both works are based on manipulating the *Atm* gene in the mouse.

*Atm* knockout mice have long been around. These mice exhibit most of the symptoms of A-T, including low body weight, sterility, radiosensitivity, and cancer predisposition, but neurodegeneration is considerably less marked in these animals compared with that observed in human A-T patients ([@bib4]; [@bib16]; [@bib36]; [@bib8]). Thus, before cancer emergence and without exposure to radiation, the murine *Atm*^−/−^ phenotype is relatively moderate. Using mutant *Atm* transgene expression in an *Atm*^−/−^ background ([@bib15]) and via direct knockin ([@bib37]), the two groups generated new mouse strains that lack Atm activity; rather than being devoid of Atm, these animals express physiological levels of catalytically inactive (kinase dead) protein. Strikingly, in both laboratories, this genotype led to early embryonic lethality, with inherent genomic instability that was higher than that observed in *Atm*^−/−^ animals ([Fig. 1](#fig1){ref-type="fig"}). Conditional expression of the mutant protein in the immune system reduced the efficiency of V(D)J (variable, diversity, and joining) recombination and immunoglobulin class switching---two processes that involve the NHEJ pathway of DSB repair and require active ATM for optimal function. However, this reduction was comparable to that caused by absence of Atm. Collectively, the data from both laboratories suggest that the HRR pathway of DSB repair, rather than NHEJ, may be affected to a greater extent by the presence of inactive Atm compared with the effect obtained after Atm loss.

![**Phenotypic comparison of mouse *Atm* genotypes.** Mice expressing an inactive protein as their sole source of Atm die in utero ([@bib15]; [@bib37]). Heterozygotes resemble wild-type (WT) animals, indicating lack of a dominant-negative effect. HRR, homologous recombination repair; kd, kinase dead.](JCB_201207063R_Fig1){#fig1}

This dramatic phenotype is presumably caused by severe malfunction of the DDR, attesting once again to its importance in early development. The critical role of the DDR in development has been documented in the past ([@bib32]), but the novelty of the current studies lies in the profound difference between Atm loss and the presence of catalytically inactive Atm. The same likely applies in humans as well: A-T patients typically exhibit ATM loss, and in rare cases of catalytically inactive ATM in patients, its level is low enough to allow for viability. A similar observation was made recently by [@bib39] with another member of the PIKK family---DNA-PKcs. This group found that mice expressing a mutant version of DNA-PKcs, lacking three phosphorylation sites associated with its activation, die shortly after birth as a result of bone marrow failure. It is interesting to note that in contrast to this, abolishing three phosphorylation sites in mouse Atm, whose equivalents in human ATM are phosphorylated during its activation ([@bib2]; [@bib25]), did not result in any discernible phenotype ([@bib31]; [@bib14]).

It appears, therefore, that the presence of physiological levels of inactive Atm severely interferes with the DDR, certainly more than its absence. Why could this be? Although the exact mechanism of this phenomenon is unknown, some assumptions can be made. ATM is recruited to DSB sites ([@bib1]) and is therefore present in the huge nuclear foci spanning these sites. Many ATM-mediated phosphorylations occur within these protein conglomerates. Importantly, the recruitment of kinase-dead Atm to sites of DNA damage was found by [@bib15] and [@bib37] to occur normally. It is possible that the presence of catalytically inactive Atm within these DDR hubs severely disturbs the ability of the cell to respond to the damage. Presumably, it interferes with the ordered temporal dynamics of events within these protein factories ([@bib28]). Deeper understanding of the spatial organization of these protein assemblies ([@bib11]) and the temporal hierarchy of events within them may elucidate ATM's role not only as an enzyme but also as a protein moiety in these structures. Of note, ATM is a large protein of 3,056 residues, of which ∼10% constitute its active site. The regulatory functions of the remaining 90% of this polypeptide are largely elusive. In a broader sense, these studies convincingly show, at the organismal level, that loss of an enzyme versus having it residing inactive in the cell can be worlds apart. In this context, it would be interesting to monitor the development of malignancies in those animals expressing the mutant Atm in their lymphoid system. This is particularly important because the malignancies observed in *Atm*^−/−^ mice, similar to A-T patients, are primarily lymphoid.

The implications for ATM-related translational research are notable. ATM has naturally been considered a potential target to be inactivated in tumor cells to selectively sensitize them to radiotherapy ([@bib6]; [@bib5]; [@bib19]). The advent of efficient ATM inhibitors ([@bib21]; [@bib18]) has further spurred these hopes. The good news is that the effect of these inhibitors on cellular radiosensitivity (and, probably, general well being) might be more profound than previously estimated, provided that these small molecules could be targeted specifically into the malignant cells. On the other hand, exposure of normal, proliferating body tissues to ATM inhibitors may be undesirable, depending on the type of tissue. Such exposure of normal tissue to ATM inhibition, even if brief, could lead to substantial genomic instability---a potential driving force toward new malignancy.
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